Curriculum Vitae

AREAS OF RESEARCH INTEREST

Acute and chronic myocardial ischemia, cardioprotection, interventional cardiology, interventional therapy in end-stage heart failure, cardiac transplantation, sexual function and cardiac disease.

  PROFESSIONAL MEMBERSHIPS

German Society of Cardiology/Heart & Circulation Research (10/1/1987 - present)

European Society of Cardiology, elected Fellow (FESC, 08/25/2000 - present)

American College of Cardiology, elected Fellow (FACC, 08/31/2001 -  present)

Saudi Heart Association (12/1/2000 - present)

Heart Failure Society of America (5/1/2003 - present)

Society of Coronary Angiography and Intervention, elected fellow (FSCAI, 09/15/2004 - present)

European Association of Percutaneous Cardiovascular Interventions (EAPCI)

  MAJOR CLINICAL INTERESTS

Interventional cardiology, acute and chronic myocardial ischemia, heart failure, sexual function and cardiac disease, cardiac transplantation.

Medical Licenses:    

Texas Medical Board, License # M3380

Medical Board of California, # A 104432


  Administrative Positions

Chairman, Heart Failure Committee

Member, IRB

Member, Performance Improvement Committee

Member, Committee on Hospital Resource Utilization

Member, M & M Committee

Member, Graduate Medical Education Committee

Director, Heart Failure/Transplant Fellowship Program

Member, National Heart, Lung, and Blood Institute (NHLBI) Specialized Centers for Cell-Based Therapy (SCCT)

Member, Committee on Community Education

EDUCATION

7/1980-1981       Medical training at the Faculty of Medicine, University of Vienna, Austria

10/1980-7/1987  Medical training at the Faculty of Medicine, Philipps-UniversityMarburg, Germany

8/1986-10/1986  Training in Surgery  at the Faculty of Health Sciences, Ife University Teaching Hospital Complex, Ile-Ife, Nigeria

6/1987-4/1990    Residency in Internal Medicine and Cardiology, Community HospitalEschwege, Germany

1987                    Doctoral degree/thesis, Dr. med. univ./PhD, University of Vienna, Austria

1989                   Doctoral degree/thesis, Dr. med./MD, Philipps-University Marburg,Germany

4/1990-6/1991    Research fellowship (German Heart Foundation) at the Max Planck-Institute (Prof. Dr. W Schaper), Bad Nauheim, Germany

7/1991-10/1996  Fellowship in Internal Medicine and Cardiology, Med. Klinik I (Prof. Dr. P Hanrath), RWTH University Hospital Aachen, Germany

10/1996-3/1998  Research Fellowship at the Heart Institute (RA Kloner, MD, PhD, Program Director) Good Samaritan Hospital & Division of Cardiology, University of Southern California, Los Angeles, CA

  PROFESSIONAL WORK HISTORY

1/1996-10/2000       Faculty, Consultant Cardiologist, Interventional Cardiologist, Clinical Supervisor (Oberarzt), Director of Heart Failure & Transplant Program, Director of Cardiophysiology Research, Interim Supervisor for the Coronary Care Units/Intensive Care Units at the Medical Clinic I, RWTH University Hospital Aachen, Germany

1/1998-2/2003         Faculty position, Associate Professor of Medicine, RWTH University Hospital Aachen, Germany

6/1999                     Thesis/Habilitation and Venia legendi, School of Medicine, RWTH University Hospital, Aachen, Germany

10/2000-2/2003       Head & Chairman of the Department of Cardiology, Consultant Cardiologist, Director of the ICUs, Director of the Cardiac Catheterization Laboratories, Professor of Medicine, Dr. S. Fakeeh Hospital, Harvard Medical International, Jeddah, Saudi Arabia

2/2003-4/2006         Faculty, Professor of Medicine, Medical Director of Heart Failure and Transplantation, Department of Internal Medicine, Division of Cardiology, The University of Texas Medical Branch, Galveston, TX

4/2006 – 1/2012      Faculty, Professor of Medicine, ULCA David Geffen School of Medicine, Los Angeles, CA

BOARD CERTIFICATION

07/12/1995   Internal Medicine (German Facharzt), Physicians’ Chamber Nordrhein, Tersteegenstrasse, Duesseldorf, Germany

12/09/1998   Cardiology (German Facharzt), Physicians’ Chamber Nordrhein, Tersteegenstrasse, Duesseldorf, Germany

06/12/2000   Internal Intensive Care Medicine (German Facharzt), Physicians’ Chamber Nordrhein, Tersteegenstrasse, Duesseldorf, Germany 

03/31/2005   American Board of Internal Medicine approval as “Candidate for Special Consideration“ (board eligible) for Internal Medicine

08/14/2007   Board Certification in Internal Medicine, Diplomate of the American Board of Internal Medicine, ABIM # 277824

09/2007        American Board of Internal Medicine, approval as “Candidate for Special Consideration“ (board eligible) for Cardiovascular Diseases, ABIM # 277824

11/05/2008   Board Certification in Cardiovascular Diseases (Cardiology),           Diplomate of the American Board of Internal Medicine, ABIM # 277824

11/8/2010     Board Certification in Advanced Heart Failure/Heart Transplant Cardiology,American Board of Internal Medicine, ABIM # 277824

  TEACHING EXPERIENCE

7/1987-4/1990         Lecturer/teacher for Internal Medicine (4 hours weekly), Nursing School, District Hospital Eschwege, Germany

10/1987-5/1990       Lecturer/teacher for Medicine (2 hours weekly), School for nursing of the elderly (Altenpflegeschule) in Eschwege, Germany

5/1990-6/1991         Lecturer/teacher for acute medical emergencies (1 hour weekly), Red Cross Bad Nauheim, Germany

7/1991-10/2000       Lecturer/teacher (altogether 3 hours weekly/semester), RWTH University Aachen, Germany in

  • Propedeutics (introduction in scientific work)
  • Cardiovascular physiology for clinical semesters
  • Clinical cardiology for clinical semesters (in collaboration with my colleagues)
  • Bedside cardiology for pre-and postgraduates
  • ICU grand rounds
  • Acute emergency course
  • Acute chest pain: differential diagnostics
  • ECG courses I and II
  • ICU-monitoring coursE

10/2000-1/2003       Lecturer/teacher (block courses, altogether 20 hours per semester), RWTH University Aachen, introduction in cardiovascular research and practice

  • Block A: New ischemic syndromes: stunning, hibernating, preconditioning. Study design
  • Block B: From basic research to bedside: acute myocardial ischemia, myocardial infarction, therapeutic angiogenesis, cell transplantation, stem cell research
  • Block C: Careers in cardiology: Basic research institutions, university hospitals, community hospitals

10/2000-1/2003       Lecturer/teacher in BLS & ACLS training courses (2 hours weekly), Harvard Medical International Dr. Fakeeh Hospital Jeddah, Saudi Arabia

2/2003-4/2006         Lecturer/teacher in Cardiology at UTMB

  • Teaching cardiology for School of Medicine
  • Teaching internal medicine residents as attending faculty
  • Teaching cardiology fellows as faculty in cardiology
  • Teaching interventional cardiology fellows as faculty interventional cardiologist

4/2006-current        Lecturer/teacher in Internal Medicine and Cardiology at UCLA/Cedars Sinai Medical Center, Professor of Medicine, and also at UC Riverside (since 2016).

AREAS OF RESEARCH INTEREST

Acute and chronic myocardial ischemia, cardioprotection, interventional cardiology, interventional therapy in end-stage heart failure, cardiac transplantation, sexual function and cardiac disease.

PROFESSIONAL MEMBERSHIPS

German Society of Cardiology/Heart & Circulation Research (10/1/1987 - present)

European Society of Cardiology, elected Fellow (FESC, 08/25/2000 - present)

American College of Cardiology, elected Fellow (FACC, 08/31/2001 -  present)

Saudi Heart Association (12/1/2000 - present)

Heart Failure Society of America (5/1/2003 - present)

Society of Coronary Angiography and Intervention, elected fellow (FSCAI, 09/15/2004 - present)

European Association of Percutaneous Cardiovascular Interventions (EAPCI)

MAJOR CLINICAL INTERESTS

Interventional cardiology, acute and chronic myocardial ischemia, heart failure, sexual function and cardiac disease, cardiac transplantation.

ADDITIONAL INFORMATION

Reviewer for scientific journals (or member of editorial boards 1996 –2009)

European Heart Journal

Journal of Molecular Medicine

Laboratory Investigation

The New England Journal of Medicine

Circulation

Circulation Research

Journal of Clinical Investigation

American Journal of Cardiology

American Heart Journal

The Journal of Thoracic and Cardiovascular Surgery

Medizinische Klinik

Zeitschrift für Rheumatologie

Basic Research in Cardiology

Journal of Pharmacological Sciences (formerly: Japanese Journal of Pharmacology)

Journal of the American College of Cardiology

Pharmacology

Journal of Zhejiang University SCIENCE (JZUS, China), The International Journal

Cardiovascular Drugs and Therapy

International Journal of Impotence Research

Cardiovascular Drugs and Therapy

Diabetes Research and Clinical Practice

Andrology 

Revista Española de Cardiología

The Journal of Sexual Medicine

Indian Journal of Medical Research

Journal of Andrology

Growth Hormone & IGF Research

Urology 

Journal of Cardiac Failure

Cardiology 

Journal of Postgraduate Medicine 

Journal of Urology

Expert Review of Cardiovascular Therapy

Growth Hormone & IGF Research 

Pharmacological Research

Expert Opinion on Emerging Drugs

Future Drugs

Future Medicine

Women’s Health

Editorial Board Memberships

Journal of Cardiovascular Pharmacology and Therapeutics
http://www.sagepub.com/journalsProdEditBoards.nav?prodId=Journal201790

International Journal of Impotence Research
http://www.nature.com/ijir/about.html

Journal of Geriatric Cardiology 

Saudi –German Medical Journal
http://www.sghgroup.com/sghmj/index.php?P=Board 

Expert Review of Cardiovascular Therapy
http://www.expert-reviews.com/page/journal/erc/editors.jsp

Journal of Clinical Rehabilitative Tissue Engineering (International Editor)
http://www.crter.org/Html/2009_04_07/2025_25143_2009_04_07_41059.html

Middle East Journal of Age and Ageing
http://www.me-jaa.com/EDITORIALBOARD.htm 

Cardiology Management Journal
http://www.cardiologymanagement.eu/index.php?id=editorial

Cardiovascular Diabetology
http://www.cardiab.com/edboard/

Cardiovascular Journal of Africa

Expert Opinion On Pharmacotherapy

 Iranian Cardiovascular Research Journal
http://www.icrj.ir/UI/Pblc/HtmlPage.aspx?pn=ViewEditBord

Chairman / Scientific Faculty / Scientific Advisory Board Positions

Education in Internal Medicine [Internistische Weiterbildung}. District Hospital [Kreiskrankenhaus] Eschwege, Germany, Apr 12,1989.

Management of acute ischemic syndromes. Munich, Germany, Oct 27, 1999

TEN-HMS – telemedicine in heart failure. Cologne, Germany, Oct 5, 2000.

Therapeutic angiogenesis [Therapeutische Angiogenese]. Eschwege, Germany, May 18, 2000

2. Workshop cardiology, Klinikum Hoyerswerda, Germany, May 30, 2000.

Working group thoracic organ transplantation, German society of cardiology [Deutsche Gesellschaft für Kardiologie], Mannheim, Germany, Apr 10, 2000.

Integrated clinical and experimental findings in myocardial ischemia, University of Leuven, Leuven, Belgium, Dec 18, 1994.

Health Fair [Gesundheitsmesse] 1995, Essen, Germany, Sep 7-10, 1995.

Health Fair [Gesundheitsmesse] 1996, Essen, Germany, Sep 2-5, 1996.

Atherosclerosis – new aspects in diagnosis and therapy [Atherosklerose - Neue Aspekte in Diagnostik und Therapie], Aachen, Germany, Nov 13, 1998.

Spring Meeting of the German Society of Cardiology [Frühjahrstagung der Deutschen Gesellschaft für Kardiologie], Mannheim, Germany, Apr 20, 2000.

Mangement of acute coronary syndromes. Amman, Jordan, Nov 8, 2001.
<td style="width: 25%; height: 9px; vertical-align: top;"><strong>Chairman / Scientific Faculty / Scientific Advisory Board Positions</strong></td>
  <td style="width: 75%; height: 9px; vertical-align: top;">
  <ol>
  <li>Education in Internal Medicine [Internistische Weiterbildung}. District Hospital [Kreiskrankenhaus] Eschwege, Germany, Apr 12,1989.</li>
  <li>Management of acute ischemic syndromes. Munich, Germany, Oct 27, 1999</li>
  <li>TEN-HMS &ndash; telemedicine in heart failure. Cologne, Germany, Oct 5, 2000.</li>
  <li>Therapeutic angiogenesis [Therapeutische Angiogenese]. Eschwege, Germany, May 18, 2000</li>
  <li>2. Workshop cardiology, Klinikum Hoyerswerda, Germany, May 30, 2000.</li>
  <li>Working group thoracic organ transplantation, German society of cardiology [Deutsche Gesellschaft f&uuml;r Kardiologie], Mannheim, Germany, Apr 10, 2000.</li>
  <li>Integrated clinical and experimental findings in myocardial ischemia, University of Leuven, Leuven, Belgium, Dec 18, 1994.</li>
  <li>Health Fair [Gesundheitsmesse] 1995, Essen, Germany, Sep 7-10, 1995.</li>
  <li>Health Fair [Gesundheitsmesse] 1996, Essen, Germany, Sep 2-5, 1996.</li>
  <li>Atherosclerosis &ndash; new aspects in diagnosis and therapy [Atherosklerose - Neue Aspekte in Diagnostik und Therapie], Aachen, Germany, Nov 13, 1998.</li>
  <li>Spring Meeting of the German Society of Cardiology [Fr&uuml;hjahrstagung der Deutschen Gesellschaft f&uuml;r Kardiologie], Mannheim, Germany, Apr 20, 2000.&nbsp;</li>
  <li>Mangement of acute coronary syndromes. Amman, Jordan, Nov 8, 2001.&nbsp;</li>
  <li>The new role of antiplatelet drugs. Combined meeting of the European Society of Cardiology &amp; the Egyptian Society of Cardiology, Cairo, Egypt, Feb 21, 2002.</li>
  <li>Current trends in cardiovascular medicine. Harvard Medical International, Jeddah, Saudi Arabia, Jan 6, 2003&nbsp;</li>
  <li>The tenth annual essentials in internal medicine: update on principles and practice and Department of Internal Medicine Alumni Society and Scientific Meeting, Galveston, TX, Apr 24-26, 2003.</li>
  <li>Second UTMB heart failure symposium, Galveston, TX, Apr 26, 2003.</li>
  <li>Scientific advisory board GSK for heart failure management, Houston, TX, Jun 12, 2003</li>
  <li>National GSK advisory board for heart failure, Philadelphia, PA, Jul 20, 2003</li>
  <li>Basic science advisory board for electrical therapy in heart failure, Heart Failure Society of America, Las Vegas, NV, Sep 19, 2003</li>
  <li>Advisory board for the use of eptifibatide in ACS, Millenium, Houston, TX, Feb 26, 2004</li>
  <li>Scientific GSK advisory board for heart failure management, New Orleans, LA, Mar 5, 2004</li>
  <li>AVENTIS SYNERGY investigator meeting, Dallas, TX, Jun 12, 2004</li>
  <li>Carvedilol advisory board, San Diego, CA, Nov 11-13, 2004</li>
  <li>Course director, cardiovascular CME symposium &ldquo;Sex and the Heart&ldquo;, Galveston, TX, Apr 23, 2005</li>
  <li>Scientific Faculty, Chairman, Controversies in Cardiovascular Diseases, Cedars-Sinai Medical Center, Santa Monica, CA, Oct 6-8, 2005</li>
  <li>Course director, cardiovascular CME symposium &ldquo;Sex and the Heart&ldquo;, Galveston, TX, Apr 1, 2006</li>
  <li>CACHED (Clinical Alliance on Cardiovascular Health and Erectieol Dysfunction) Leadership Counsil, CVicago, IL, September 15-16, 2006</li>
  <li>Scientific Faculty, St. Jude Heart Failure Meeting, San Francisco, CA, August 2006</li>
  <li>Scientific Faculty &amp; Chairman, Controversies in Cardiovascular Diseases, the 6<sup>th</sup> in the series, Beverly Hills, CA, September 2006</li>
  <li>Scientific Faculty Panelist, Harvard Educational Series, NSAIDs and cardiovascular risk, Boston, MA, February 15, 2007</li>
  <li>Scientific Faculty Panelist, Medical Crossfire, Coxibs or NSAIDs? Individualizing therapy to manage risk. Amercian College of Cardiology New Orleans, LA, March 24, 2007</li>
  <li>Scientific Faculty, GI bleeding and cardiovascular risks: New evidence weighs into the NSAID controversy. Digestive Disease Week Washington, D.C., May 20, 2007</li>
  <li>Scientific faculty, J&amp;J Heart Failure meeting, San Francisco, CA, August 18-22, 2007</li>
  <li>Chairman, Symposium: The use of mechanical dyssynchrony versus wide QRS in the decision process for CRT, Heart Failure Society of America, Washington, D.C., September 17, 2007</li>
  <li>Scientific faculty, Controversies and advances in the treatment of cardiovascular disease, Beverly Hills, CA, October 4-5, 2007</li>
  <li>Scientific faculty, Controversies and advances in the treatment of cardiovascular disease, Beverly Hills, CA, October 1-2, 2009</li>
  <li>Faculty, Scottsdale Cardiac Rhtythm Management Summit, Scottsdale, AZ, November 7-9, 2009</li>
  <li>Scientific Faculty &amp; Session Chair, International Conference on Blood Purification, Marina Del Rey, June 2010</li>
  <li>Scientific faculty &amp; Session Chair, Controversies and advances in the treatment of cardiovascular disease, Beverly Hills, CA, October, 2010</li>
  <li>Scientific faculty, Advanced heart failure &amp; Transplant Cardiology Course, Los Angeles, October 2010.</li>
  </ol>
  </td>

Principal investigator

I) District Hospital Eschwege, Germany

1987-1991 LIMITS, Liquemin in myocardial infarction during thrombolysis with saruplase. Sponsor: Gruenenthal, $ 15,000 

II) Max-Planck-Institute Bad Nauheim, Germany

1990-1991 Stunned and preconditioned myocardium, Sponsor: German Heart Foundation. Personal research scholarship, $ 35,000

III)        University Hospital RWTH Aachen, Germany

1992/1993 Antiapoptosis in experimental myocardial ischemia. Sponsor: Hoffmann-La Roche, $ 35,000

1994-1999 Antiapoptosis in human hibernating myocardium, Sponsor: La Roche, $ 70,000

1995-1998 EXP 3174 myocardial protection study: Sponsor: MSD, $ 70,000

1997-2000 Stunning myocardium and MRI. Sponsor: Schering, $ 55,000

1996-1998 Experimental hibernating myocardium. Sponsor: START Governmental Foundation Nordrhein, $ 18,000

1998-2000 Hemodynamics in myocardial bridging. Sponsor: START Governmental Foundation Nordrhein, $ 13,000

1999-2000 TEN-HMS: Trans-European Telemedicine Network Heart Failure Home Monitoring Study. Sponsor: European Union, $ 360,000

1999-2001 CAESAR I: Clinical American and European Studies of Angina and Revascularization. Sponsor: Pfizer, $ 46,000

IV) University of Southern California, Los Angeles, USA

1996-1998 Angiogenesis and cell transplantation, Sponsor: NIH (RO 1) $ 1.000,000

Coinvestigator

V) University of Texas Medical Branch, Galveston, USA

Principal investigator

1)        2003-2006 ADHERE, Acute decompensated heart failure registry, Sponsor: Scios, $ 3,000

2)        2003-2006 ADVANCENT, National Registry to Advance Heart Health, Sponsor: Guidant, $ 36,000

3)        2003-2007 WARCEF, Warfin vs. aspirin in reduced cardiac ejection fraction, Sponsor:  NIH, $ 326,000 (currently on hold)

4)        2004-2006 EVEREST, Efficacy of vasopressin antagonism in heart failure: outcome study with Tolvaptan, Sponsor: Otsuka, $ 65,000

5)        2004-2006 ACCLAIM, A multi-center, randomized, double-blind, parallel group, placebo-controlled study to assess the effects of immune modulation therapy (IMT) on mortality and morbidity in patients with chronic heart failure, Sponsor: Vasogen, $ 360,000

6)        2004-2006 REVIVE, Randomized multicenter evaluation of intravenous levosimendan efficacy versus placebo in the short term treatment of decompensated chronic heart failure, Sponsor: Orion/Abbott, $ 60,000

7)        2004-2006 A-HEFT, African-American heart failure trial. A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure, Sponsor: Nitromed, $ 63,000

8)        2005-2007 DITPA, A single multicenter randomized double-blind, placebo-controlled study of DIPTA in patients with NYHA class III and IV congestive heart failure who have low serum T3 levels, Sponsor: Titan Pharamceuticals, $  60,000

Co-Investigator

9)        2004-2006, ARRIVE 2, A multi-center safety surveillance registry. Sponsor: Boston Scientific, $ 150,000

10)      2004-2006, EARLY ACS,  Early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome: a randomized, placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome, Sponsor: Millenium, $ 75,000

Co-Investigator in NIH-funded Research

1996-1998 Angiogenesis and cell transplantation, Sponsor: NIH (RO-1) $ 1.000,000

Co-applicant for NIH RO-1 Nutrition and Heart Failure, re-submitted 

PI applicant for NIH RO-3, Heart failure & cardiac transplantation, re-submitted

Current Committee Memberships

IRB 1, Cedars Sinai Medical Center, Los Angeles, CA, USA, January 2008

UCLA Committee on Continuing and Community Education, Los Angeles, CA, USA, effective September 1, 2008.

National Heart, Lung, and Blood Institute (NHLBI) Specialized Centers for Cell-Based Therapy (SCCT), Bethesda, USA, January 2008

Book Chapters

Schwarz ER. The course of pepsin in the stomach after proximal selective vagotomy. [Der Verlauf des Pepsinspiegels im Magensaft nach selektiv proximaler Vagotomie]. Disserationsschrift Philipps-Universitaet Marburg, Germany, 1989.

Schaper J, Schwarz ER, Elsasser A. The ultrastructure of hibernating myocardium. in: Stunning and hibernation in the heart, eds. R Ferrari & P Harris, 72-74, Canal Press, Venice, 1993.

Schwarz ER, Montino H, Fleischhauer J. Das Schweineherz als ein geeignetes Modell zur Untersuchung von Myokardinfarkt, ventrikulärer Kontraktilität und Myokardprotektion. [The pig heart as a suitable model for studying myocardial infarction, contractility, and myocardial protection]. In: Versuchstiere- Qualitätssicherung in Humanmedizin und biologischer Forschung [Experimental animals in medicine and research], editor W Küpper, Universitätsdruckerei FEM & GV SOLAS, FU Berlin 24-36; 1997.

Schwarz ER, Hammerman H, Kloner RA. Q-wave myocardial infarction. In: Current Practice in Medicine, 2nd edition, Roger C. Bone, Series Editor, Joseph S. Alpert, Section Editor. Current Medicine, Philadelphia. 1998.

Schwarz ER, Hammerman H, Kloner RA. Q-wave myocardial infarction. In: Current Practice in Medicine, 3rd edition, Roger C. Bone, Series Editor, Joseph S. Alpert, Section Editor. Current Medicine, Philadelphia. 1999.

Schwarz ER, Hammerman H, Kloner RA. Q-wave myocardial infarction. In: Cardiology for the Primary Care Physician, 3rd edition, J. S. Alpert, editor, Current Science Group, Philadelphia. 1999.

Schwarz ER. Koronarangiographische Befunde und intravaskulaere Haemodynamik by symptomatischen Patienten mit koronaren Muskelbruecken: eine Untersuchung zur klinischen und funktionellen Bedeutung und Therapie dieser haeufigsten Koronaranomalie. [Coronary angiographic findings and intravascular hemodynamics in symptomatic patients with myocardial bridging – a study to assess functional and clinical relevance of the most common coronary anomaly]. Habilitationsschrift RWTH Universitaetsklinikum Aachen, Germany, 1999.

Schwarz ER, Skobel EC. Q-wave myocardial infarction. In: Current Practice of Medicine and Cardiology for thr Primary Care Physician, GSG Philadelphia, Current Sciences, Philadelphia, PA, 2001.

Schwarz ER, Gupta R. Non-ST segment elevation myocardial infarction. In: Cardiology for the Primary Care Physician, 4th edition, Current Sciences, Philadelphia, PA, 2005.

IsHak WW, Stewart S, Pechnik R, Huang W, Schwarz ER. Substance induced sexual disorders. Chapter 3, in: Guidebook of Sexual Medicine, ed. Waguih W. Ishak, A&W Publishing Group, Beverly Hills, CA, 2008.

IsHak WW, Amiri SR, Schwarz ER. Sexual disorders due to general medical conditions. Chapter 4, in: Guidebook of Sexual Medicine, ed. Waguih W. Ishak, A&W Publishing Group, Beverly Hills, CA, 2008.

Revised 2nd edition, Jan 2017.

Chien C, Schwarz ER. Erectile dysfunction and cardiovascular disease. In: Cardiology for the boards, 2010

Baraghoush A, Phan A, Willix RD, Schwarz ER. Erectile dysfunction as a complication of heart failure. Current Heart Failure Reports, 2010

Schwarz ER. Erectile Dysfunction, in Textbook of Internal Medicine, Springer, 2014.

Books 

Schwarz ER. Sex and the Heart. Friedel & Ernst Academic Publishing, Los Angeles, CA & Haldorf, Germany, 2006 (http://sexandtheheart.com). 

Erectile Dysfunction. Edited by Schwarz, ER. Oxford University Press, 2013.

ABSTRACTS

Schwarz ER, K Thon, S Massarrat. Course of pepsin activity in serum after vagal stimulation in patient swith vagotomy, peptic ulcer disease, and controls. [Verlauf der Pepsinaktivität (PA) im Serum unter vagaler Stimulation bei Patienten mit Vagotomie und Ulcus duodeni und Kontrolle]. Schmidt, Caspary: Results in gastroenterology. [Ergebnisse der Gastroenterologie], 41. Conference of German Society of Gastroenterology [41. Tagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten]. Gastroenterolgie Suppl 41, 12; 1986.

Massarrat S, Timmer A, Schwarz ER. Vagal-induced increase of serum pepsin activity in patients with peptic ulcer disease and its relation to gastic acid secretion and severity of the disease. [Vagus-induzierter Anstieg der Pepsinaktivität im Serum der Patienten mit Ulcus duodeni und seine Beziehung zur Säuresekretion und zur Schwere des Leidens]. Gastroenterologie Suppl 44, 181; 1989.

Sack S, Mohri M, Schwarz ER, Arras M, Schaper W. Effect of ischemic preconditioning (PRECON) on regional myocardial dysfunction caused by coronary occlusion (CO) in closed-chest pigs. J Mol Cell Cardiol 23, Suppl. V-112, 1991.

Mohri M, Zimmermann R, Bernotat-Danielowski S, Sack S, Schwarz ER, Arras M, Schaper J, Schaper W. Coronary microembolization increases growth factor expression in porcine hearts. Circulation 84:4 Suppl. II-395; 1991.

Schwarz ER, Mohri M, Sack S, Arras M, Schaper W. Duration of infarct size limiting effect of ischemic preconditioning in the pig. Circulation 84:4 Suppl. II-432;1991.

Schwarz ER, Mohri M, Sack S, Arras M, Schaper W. The role of adenosine and its A1-receptor in ischemic preconditioning. Circulation 84, 4 Suppl. II-191;1991.

Schwarz ER, Mohri M, Stefan Sack S, Arras M, Schaper W. Preconditioning by ischemia lasts only for 30 minutes and is inhibited by adenosine antagonists. J Mol Cell Cardiol 24 Suppl I:93;1992.

Schwarz ER, Mohri M, Sack S, Arras M, Schaper W. Long-lasting dysfunction and short-lasting increase in ischemic tolerance following coronary occlusion. [Langanhaltende Dysfunktion und kurzdauernde Ischämietoleranzerhöhung nach Koronarokklusion]. Z Kardiol 81 Suppl I:168;1992.

Schwarz ER, Mohri M, Sack S, Arras M, Schaper W. Adenosine antagonists impair postischemic myocardial function in swine. [Adenosin Antagonisten verschlechtern die postischämische myokardiale Funktion beim Schwein]. Z Kardiol 81 Suppl I:169;1992.

Sack S, Mohri M, Schwarz ER, Arras M, Schaper W. Can ischemic preconditioning be renewed? J Mol Cell Cardiol 24 Suppl I:92;1992.

Sack S, Mohri M, Schwarz ER, Arras M, Schaper J, Schaper W. Inhibition of Na/H exchange prevents ventricular fibrillation and preserves function in porcine stunned myocardium. Sapporo Stunned Myocardium 1:7; 1992.

Sack S, Mohri M, Schwarz ER, Arras M, Schaper J, Schaper W. Blockage of Na/H channel prevents ventricular fibrillation and improves function in stunned myocardium. [Blockade des Na/H Kanals verhindert Kammerflimmern und verbessert die Funktion im "stunned myocardium"]. Z Kardiol 81 Suppl I:119;1992.

Sack S, Mohri M, Schwarz ER, Arras M, Schaper J, Schaper W. Ischemic preconditioning – is there any clinical relevance? [Hat die ischämische Präkonditionierung klinische Bedeutung?] Z Kardiol 81 Suppl I:89;1992.

Mohri M, Sack S, Schwarz ER, Arras M, Schaper J, Schaper W. Localization of plasminogen activators and type-1 inhibitor in the mi­croembolized ischemic porcine heart. Sapporo Stunned Myocardium 1;5:1992.

Sack S, Mohri M, Schwarz ER, Arras M, Schaper J, Schaper W. Expression of aFGF in porcine myocardium depends on severity of ischemia. Sapporo Stunned Myocardium 1;5:1992.

Schwarz ER, Schaper J, vom Dahl J, Grohmann B, Uebis R, Schöndube F, Altehoefer C, Buell U, Mess­mer BJ, Sheehan FH, Schaper W. Is there a correlation between regional wall motion, glucose metabolism, and ultrastructural changes in the myocardium in chronic ischemia? [Gibt es bei der chronischen Ischämie eine Korrelation zwischen regionaler Ventrikelfunktion, Glukosemetabolismus und ultrastrukturellen Veränderungen im Myokard?] Z Kardiol 82 Suppl I:69;1993.

Sack S, Schaper J, Mohri M, Bernotat-Danielowski S, Arras M, Schwarz ER, Schaper W. Micro-necrosis is a requirement for angiogenesis. [Mikronekrosen sind eine Voraussetzung für Kollateralwachstum (Angioge­nese)]. Z Kardiol 82 Suppl I:116;1993.

Schwarz ER, Klues H, Krebs W. Evaluation of coronary blood flow velocities by intravascular Doppler during provocative maneuvers in coronary muscle bridging. Eur Heart J 14 Suppl:P783;1993.

Schwarz ER, Schaper J. Is there a correlation between different ultrastructural states of regional chronic ischemic myocardium, functional and metabolic findings? Eur Heart J 14 Suppl:P1673;1993.

Schwarz ER, Schaper J, vom Dahl J, Buell U, Schoendube F, Hanrath P. Hibernating myocardium shows different degrees of structural adaptation and its functional downregulation is not sufficient to prevent structural deterio­ration. J Am Coll Cardiol 1A: 862-25;1994.

Schwarz ER, Klues HG, Krebs W, vom Dahl J, Hanrath P. Incomplete diastolic relaxation during tachycardia explains ischemic symptoms in patients with myocardial bridging. [Inkomplette diastolische Relaxation während Tachykardie erklärt Ischä­miesymptome bei Patienten mit koronarer Muskelbrücke]. Z Kardiol 83 Suppl. I:76;1994.

Schwarz ER, Schaper J, vom Dahl J, Grohmann B, Buell U, Hanrath P. Hibernating myocardium - functional recovery is associated with a variety of ultrastructural degeneration with preserved viability. Eur Heart J 15 Suppl: 895;1994.

Strasser R, Arras M, Vogt A, Elsässer A, Schwarz ER, Schlepper M, Schaper W. Preconditioning of porcine myocardium: How much ischemia is required for induction? What is its duration? Is a renewal of effect possible? Circulation 90:579;1994.

vom Dahl J, Altehoefer C, Schwarz ER, Beilin I. Reversibility of preoperative resting perfusion defects as assessed by my­ocardial scintigraphy with Tc-99m isonitriles following successful coronary revascularization. Circulation 90:1694;1994.

Schwarz ER, Schaper J, vom Dahl J, Schaper W, Buell U, Hanrath P. Myocardial hibernation is not sufficient to prevent morphological disar­rangements with ischemic cell alterations and increased fibrosis. Circulation 90:2028;1994.

Schwarz ER, vom Dahl J, Klues HG. ß-blocker therapy improves coronary flow alterations and alleviates ischemic symptoms in patients with myocardial muscle bridges. Circulation 90:2629;1994.

vom Dahl J, Altehoefer C, Schulz G, Schwarz ER, Buell U, Hanrath P. Reversible resting Tc-99m sestamibi defects following coronary revascularization indicate underestimation of myocardial viability by resting sestamibi scintigraphy. J Nucl Cardiol 2:S4;1995. Finalist for Young Investigator Award, Cannes 1995.

Schwarz ER, vom Dahl J, Schaper J, Altehoefer C, Schaper J, Schaper W, Buell U, Hanrath P. Ultrastructural analysis reveals different degrees of morphological degeneration in hibernating myocardium. J Nucl Cardiol 2:S46;1995. Finalist for Young Investigator Award, Cannes 1995.

Schwarz ER, Montino H, Klues HG, Hanrath P. Selective angiotensin II receptor antagonism does not influence myocardial stunning but augments ischemic preconditioning in the pig heart. J Am Coll Cardiol 163A; 1995.

vom Dahl J, Altehoefer C, Büchin P, Schulz G, Beilin I, Schwarz ER, Schöndube F, Messmer BJ, Buell U, Hanrath P. Long-term follow-up in patients with CAD: nuclear viability testing and prognosis. [Langzeitverlauf bei Patienten mit koronarer Herzkrankheit: Nuklearmedizinische Vitalitätsdiagnostik und Prognose]. Z Kardiol 84 Suppl 1:3;1995.

vom Dahl J, Altehoefer C, Schulz G, Beilin I, Schwarz ER, Buell U. Reversibility of Tc 99m isonitril defects after successful revascularization. [Reversibilität von Tc 99m Isonitril (MIBI) Defekten nach erfolgreicher Koronarrevaskularisation: Hinweise für eine präoperative Unterschätzung der Myokardvitalität durch MIBI]. Z Kardiol 84 Suppl:118;1995.

Schwarz ER, Klues HG, vom Dahl J. Betablockers improve phasic blood flow velocities and eliminate angina in patients with myocardial bridging. [ß-Blockertherapie verändert die phasischen Blutflußgeschwindigkeiten und eliminiert pectanginöse Beschwerden bei Patienten mit koronaren Muskelbrücken]. Z Kardiol 84 Suppl 1:177;1995.

vom Dahl J, Altehoefer C, Buechin P, Schulz G, Schwarz ER. Long-term follow-up of patients undergoing combined nuclear viability imaging with Tc-99m sestamibi scintigraphy and F-18 fluorodeoxyglucose positron emission tomography. Eur Heart J 16:371;1995.

Schwarz ER, Montino H, Fleischhauer J, Hanrath P. The role of angiotensin II-receptor antagonism potentiates myocardial protection in the pig heart. Eur Heart J 16:339;1995.

Schwarz ER, Klues HG, vom Dahl J. ß-blocker therapy attenuates luminal diameter reductions, reduces phasic blood flow velocities, and alleviates anginal symptoms in patients with myocardial bridges. Eur Heart J 16:386;1995.

Schwarz ER, Fleischhauer J, Schütz T, Foresti M, Chakupurakal R, vom Dahl J, Klues HG. Angiotensin II receptor antagonism reduces infarct size in the pig heart. Circulation 92:I-454-55;1995.

Schwarz ER, Schaper J, vom Dahl J, Schöndube F, Buell U, Hanrath P. Cardiac adaptation to chronic ischemia is insufficient to preserve contractile function and structural integrity in human hibernating myocardium. Hung Soc Cardiol 13:5; 1996.

Schwarz ER, Fleischhauer J, Foresti M, Schuetz T, Chakupurakal R. Myocardial protection by angiotensin II receptor blockade in a model of ischemia–reperfusion in the pig heart. [Myokardprotektion durch Angiotensin II Rezeptor Blockade im Ischämie-Reperfusionsmodell am Schweineherzen]. Z Kardiol 85 (Suppl 2):131; 1996.

Schwarz ER, Schaper J, vom Dahl J, Schmiedtke N, Schöndube F, Büll U, Schaper W. Preservation of structural integrity in hibernating myocardium requires early revascularization. Eur Heart J 17(Suppl):102;1996.

Schwarz ER, vom Dahl J, Koch KC, Klues HG, Hanrath P. The role of angiotensin II in ischemic preconditioning: protection is mediated by angiotensin II and can be inhibited by angiotensin II receptor blockade. J Am Coll Cardiol 27:293A; 1996.

Schulz G, Kupferschläger J, Kaiser HJ, vom Dahl J, Wagenknecht J, Schwarz ER, Margraf R, Büll U. Non-transmissive attenuation correction and scatter correction of Tc-99m cardiac SPECT in patients with and without perfusion defects. Eur J Nucl Med 23:1049; 1996.

vom Dahl J, Altehoefer C, Büchin P, Schulz G, Schwarz ER, Buell U, Hanrath P. Myocardial viability imaging using sestamibi scintigraphy and F-18-fluoro-deoxy-glucose positron emission tomography identifies patients with greatest benefit from coronary revascularization. J Am Coll Cardiol 27:300A; 1996.

Koch KC, Schulz G, vom Dahl J, Verhasselt S, Schwarz ER, Reffelmann T, Büll U, Hanrath P. Viability testing with Tl-201 SPECT: predictive value of reversibility of regional wall motion abnormalities. [Vitalitätsdiagnostik mit Tl-201 SPECT: Vorhersage der Reversibilität regionaler myokardialer Wandbewegungsstörungen]. Z Kardiol 85 (Suppl 5):81; 1996.

Koch KC, Schulz G, Verhasselt S, Schwarz ER, Reffelmann T, Büll U, vom Dahl J. Prediction of angiographically proven recovery of regional wall motion by Tl-201 myocardial scintigraphy. Circulation 94:I-239; 1996.

Schwarz ER, vom Dahl J, Schaper J, Schmiedtke N, Schoemdube F, Schaper W. Downregulation in hibernating myocardium is a time-dependent process and preservation of structural integrity requires early revascularization. J Am Coll Cardiol 27:220A; 1997.

Klues HG, Schwarz ER, vom Dahl J, Haager P, Hanrath P. Intracoronary stent implantation - a new therapeutical approach in highly symptomatic patients with myocardial bridging. J Am Coll Cardiol 29:220A; 1997.

Klues HG, Schwarz ER, vom Dahl J, Reffelmann T, Minartz J. Intracoronary stent implantation – alternative therapy in symptomatic patients with myocardial bridges. [Intrakoronare Stent-Implantation - eine alternative Therapiestrategie bei symptomatischen Patienten mit Muskelbrücken]. Z Kardiol 86 (Suppl.1):52; 1997.

Klues HG, vom Dahl J, Schwarz ER, Minartz J, Reffelmann T, Hanrath P. Intracoronary stent implantation - an alternative technique for the treatment of symptomatic patients with myocardial bridging. Eur Heart J 18 (Suppl.):385; 1997.

vom Dahl J, Schwarz ER, Schaper J. “Hibernating” myocardium requires early revascularization to prevent irreversible cellular damage. J Nucl Cardiol 4 (Suppl.):18; 1997.

vom Dahl J, Schwarz ER, Schaper J, Hanrath P. Hibernating myocardium requires early revascularization to prevent irreversible structural deterioration. [Hibernating Myokard erfordert die frühzeitige Revaskularisation zur Vermeidung irreversibler struktureller Schäden]. Z Kardiol 86(Suppl. 2):180; 1997.

Schoendube FA, Schwarz ER, Doerge H, Messmer BJ, Hanrath P “Hibernating myocardium” yearns for coronary bypass grafting. Eur J Cardiovasc Surg Proc 10:394; 1997.

Schoendube FA, Schwarz ER, Doerge H, vom Dahl J, Schaper J. Hibernating myocardium is a dynamic unstable process asking for early intervention. [“Hibernating Myocardium” - ein dynamischer Prozess, der frühzeitige koronare Revaskularisation erfordert]. Thorac Cardiovasc Surg 45 (Suppl. 1):108; 1997.

Schwarz ER, Pollick C, Kloner RA. New techniques for quantitative and qualitative assessment of myocardial structure and function in the rat heart: transthoracic, transesophageal, and intracavitary echocardiography. [Neue Techniken zur quantitativen und qualitativen Evaluierung myokardialer Struktur und kontraktiler Funktion in Rattenherzen: transthorakale, transösophageale und intrakavitäre Echokardiographie]. Z Kardiol 87 (Suppl 1):145;1998.

Haager PK, Schwarz ER, Radke P, Reffelmann T, Minnartz J, vom Dahl J, Klues HG. Long-term effects of stenting myocardial bridges. [Langzeiteffekte der Stent-Implantation bei Patienten mit symptomatischen myokardialen Muskelbrücken]. Z Kardiol 87 (Suppl 1):304;1998.

Schwarz ER, Speakman MT, Patterson M, Hale SL, Kedes L, Kloner RA. Effect of intramyocardial injection of DNA expressing vascular endothelial growth factor in myocardial infarct tissue in the rat heart - angiogenesis and angioma formation. Circulation 98 Suppl. I 456; 1998.

Schwarz ER, Speakman MT, Kloner RA. A novel technique of plication without resection for treating infarct expansion and remodeling. Circulation 98 Suppl. I 418; 1998.

Schwarz ER, Kloner RA. Echocardiographic assessment of a new model for non-ischemic cardiomyopathy. [Ein neues Kleintiermodell einer nicht-ischämischen Kardiomyopathie und deren echokardiographische Evaluierung]. Z Kardiol (Suppl. III), 1998.

Janssens U, Karassimos E, Königs B, Reith S, Koch KC, Radke P, Schwarz ER. Regional pCO2 gap is not superior to intramucosal pHi with regard to outcome prediction. Crit Care Med 22:A14;1998.

Schwarz ER, Kloner RA. Modified Batista reduction as a new approach to improve cardiac function and prevent remodeling following myocardial infarction. [Eine modifizierte, nicht resezierende ‚Batista‘-Kardioreduktion als neues experimentelles Verfahren zur Verbesserung der kardialen Funktion und Verhinderung des Remodelings nach Myokardinfarkt]. Z Kardiol 88:222; 1999.

Schwarz ER, Hale S, Speakman M, Kloner RA. Intramyocardial growth factor application induces angiogenesis in the rat heart. [Intramyokardiale Injektion von VEGF-DNA induziert Angiogenese aber auch angiomatöse Tumore im chronischen Myokardinfarktmodell der Ratte]. Z Kardiol 88:44;1999.

Schwarz ER, Kloner RA. Direct VEGF therapy induces capillary growth but does not affect function in rat hearts. [Direkte Applikation der DNA für vascular endothelial growth factor (VEGF) in die Randfbereiche infarzierten Myokards induziert Angiogenese ohne Verbesserung der regionalen Myokardperfusion bei Ratten]. Z Kardiol 88:133; 1999.

Schwarz ER, Speakman M, Hale SL, Kloner RA. Intramyocardial application of vascular endothelial growth factor induces angiogenesis but does not augment myocardial perfusion in the rat heart. Eur Heart J 20:13;1999.

Haager PK, Dechene A, Radke PW, Schwarz ER, Hoffmann R, Janssens U, Klues HG, vom Dahl J. Acute and longterm results with an endoluminal polytetrafluoroethylene stent graft in patients with in-stent restenosis and venous coronary bypass grafts. Circulation 100:I-294; 1999.

Haager PK, Schwarz ER, Reffelmann T, Minartz J, Hanrath P. Two year clinical and 6 month angiographic follow-up in 11 symptomatic patients with stent implantation for coronary bridging. Am J Cardiol ;84:24P; 1999.

Janssens U, Karassimos E, Königs B, Schwarz ER, Hanrath P. Regional pCO2 arterial pCO2 gap is not superior to intramucosal pH with regard to outcome prediction. Crit Care Med 27:A54; 1999.

Krüger S, Breuer C, Seipelt I, Schwarz ER. Lung function testing to differentiate exercise capacity in chronic heart failure patients. [Lungenfunktionelle Parameter zur Differenzierung der Belastbarkeit von Patienten mit chronischer Herzinsuffizienz]. Pneumologie 54:S6; 2000.

Krüger S, Breuer C, Seipelt I, Schwarz ER. Pulmonary and endothelial function determine exercise capacity in patients with advanced heart failure. [Pulmonale Parameter und Endotheldysfunktion bestimmen die Belastbarkeit von Patienten mit chronischer Herzinsuffizienz]. Z Kardiol 89, Suppl. 5:294; 2000.

Skobel E, Reffelmann T, Schwarz ER. The effect of presynaptic nerve endings in interstitial ATP depletion. [Einfluß präsynaptischer Nervenendigungen bei der interstitiellen ATP-Freisetzung]. Z Kardiol 89, Suppl. 5; 163; 2000.

Reffelmann T, Kerstin PH, Meven DA, Skobel CE, Schwarz ER. Infarct size reduction by carvedilol and BM 91.9228. [Infarktgrößenreduktion durch Carvedilol und den Carvedilolmetaboliten BM 91.9228 bei Rattenherzen]. Z Kardiol 89, Suppl. 5:22; 2000.

Schwarz ER, Reffelmann T, Kerstin PH, Meven D, Skobel E, Hanrath P. Carvedilol and its hydroxylated metabolite BM 91.0228 induce increased tolerance towards ischemia with smaller infarcts after transient coronary occlusion in the rat heart. Eur Heart J 21:40; 2000.

Schwarz ER, Hale S, Kloner RA. Do transplanted cardiomyocytes augment global left ventricular in infarcted rat heart. Eur Heart J 21:499; 2000.

Reffelmann T, Schwarz ER, Skobel CE, Hanrath P. Activation of ATP-sensitive potassium channels in hypoxic cardiac failure is not mediated by adenosine 1-receptors in the rat heart. Eur Heart J 21:512; 2000.

Krüger S, Schwarz ER, Breuer C, Hanrath P. Pulmonary factors and endothelial dysfunction determine exercise tolerance and extent of dyspnea in patients with chronic heart failure. Eur Heart J 21:660; 2000.

Schwarz ER, Hale SL, Kloner RA. Do transplanted cardiomyocytes augment global left ventricular function in infarcted rat heart? J Am Coll Cardiol 35, Suppl A, 394A; 2000.

Hoffmann R, Haager P, Kerckhoff G, Schwarz ER, Franke A, vom Dahl J, Hanrath P. High pressure stent implantation is requested even with less rigid second generation stents to obtain large follow-up lumen dimensions. An intravascular ultrasound study. J Am Coll Cardiol 35, Suppl A, 45A; 2000.

Schwarz ER, Kersting PH, Meven P, Reffelmann T, Skobel EC, Hanrath P. Antiapoptotic effects of carvedilol are not mediated by its beta-adrenergic receptor blocking properties. J Am Coll Cardiol 37,648A; 2001.

Skobel CE, Schuh A, Reffelmann T, Kamensin S, Klosterhalfen B, Schwarz ER, Hanrath P. Fetal cardiomyocyte transplantation after myocardial infarction improves and maintains heart function on a long-term follow-up in the rat model. Eur Heart J 22: Suppl, 489; 2001.

Reffelmann T, Schwarz ER, Skobel CE, vom Dahl J, Hanrath P. Poststenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic glyburide. Eur Heart J 22: Suppl 503; 2001.

Skobel CE, Reffelmann T, Schuh A, Klosterhalfen B, Kamenzin S, Schwarz ER. Fetal cardiomyocyte transplantation after myocardial infarction improves and maintains heart function on a long-term follow-up in the rat model. Circulation 104 (Suppl), II-271, 2001.

Reffelmann T, Skobel CE, Hanrath P, vom Dahl J, Schwarz ER. Poststenotic coronary blood flow at rest is not altered by therapeutical doses of the oral antidiabetic glyburide in patients with coronary artery disease. Eur Heart J 22 Suppl 67;2001.

Lepper W, Siersweda GT, Franke A, Kamp O, de Cook CC, Schwarz ER, Voci P, Visser CA, Hoffmann R. Repeated evaluations of coronary flow profile in patients with acute myocardial infarction – comparison with IV contrast echocardiography. [Wiederholte Beurteilung des koronaren Flussprofils bei Patienten mit erstem akuten Myokardinfarkt – Vergleich mit der intravenoesen Kontrastechocardiographie]. Z Kardiol 84:111; 2002.

Schwarz ER, Meven DA, Kersting PH, Tussing T, Skobel EC, Hanrath P. Monocyte chemoattractant protein-1 induced monocyte infiltration and angiogenesis does not result in arteriogenesis or improved cardiac function in chronically infarcted myocardium. J Am Coll Cardiol 43:271A; 2004.

Schwarz ER, Diep TP, Skobel EC, Nowak B, Kostin S, Grohmann B. Carvedilol preserves cellular integrity and improves outcome in patients with chronic hibernating myocardium after revascularization. J Am Coll Cardiol 43:296A; 2004.

Kapur V, Rastogi S, Rosanio S, Schwarz ER. Significance of sexual dysfunction among patients with heart failure. Hoax or reality? J Cardiac Fail 13, S151, 2007.

Presentation awards/public media and TV presentations

Schwarz ER, vom Dahl J, Schaper J, Altehoefer C, Schaper W, Buell U, Hanrath P. Ultrastructural analysis reveals different degrees of morphological degeneration in hibernating myocardium. J Nucl Cardiol 2:S46;1995. Young Investigator Award, Cannes 1995

Schwarz ER. Frühsymptome und Akutintervention beim Myokardinfarkt - eine Standortbestimmung 1995. Gesundheitsmesse 95, Essen, Germany, September 1995.

Schwarz ER. Herztransplantation heute. TV dokumentation des WDR (West German Broadcasting Company), TV presentation, German TV channel 1 and channel WDR, October 2000.

Schwarz ER. Early symptoms for heart attack. TV presentation in Human Health, Ministry of Information, Saudi TV channel  2, Jeddah, Saudi Arabia, January 2001.

Schwarz ER. Risk factors and coronary heart disease.  TV presentation in Human Health, Ministry of Information, Saudi TV channel 2, Jeddah, Saudi Arabia, April  2001.

Schwarz ER. IRWIN award winner 2006 for “Best News-Tie In Campaign” by the Book Publicists of California for “Sex and the Heart - what women need to know about male sexual dysfunction”, Los Angeles, December 12, 2006.

45 local TV or radio presentations regarding “Sex and the Heart”, Los Angeles, CA,  October 2006 until July 2007.

KTLA Los Angeles, Sexual dysfunction as a harbinger for cardiovascular disease, Los Angeles, June 2008.

References

Dr. P.K. Shah, MD, Director, Division of Cardiology, Director, Oppenheimer Atheroscleroris Research Center, Professor of Medicine, Cedars Sinai Medical Center & UCLA, , Shapell and Webb Family Chair in Clinical Cardiology, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd., Ste. 5531 , Los Angeles, CA 90048



Phone: (310) 42313884

Email: PredimanKrishan.Shah@cshs.org

Dr. Alfredo Trento, MD, Director of the Division of Cardiothoracic Surgery, Estelle, Abe and Marjorie Sanders Endowed Chair in Cardiac Surgery, Professor of Surgery at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Cedars Sinai Heart Institute, Cedars Sinai Medicla Center, 8700 Beverly Blvd., Ste. 2S03, Los Angeles, CA 90048.



Phone: (310) 4231877

Email: Alfredo.trento@cshs.org

Dr. Andrew Klein, MD, Director, Comprehensive Transplant Center, Professor of Surgery, Esther and Mark Schulman Chair in Surgery and Transplant Medicine, Cedars Sinai Medical Center, 8635 West 3rd St.
Suite 590W, Los Angeles, CA  90048



Phone: 310-423-2641

Email: kleinas@cshs.org

Dr. Bruce L. Gewertz, MD, Surgeon-in-Chief, H and S Nichols Endowed Chair in Surgery, Chairman, Department of Surgery, Vice-President for Interventional Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., 8215 NT Los Angeles, CA 90048



Phone: (310) 4235884

Email: bruce.gewertz@cshs.org

Prof. Dr. Robert A. Kloner, MD, PhD, Director, Heart Institute, Good Samaritan Hospital, Professor of Medicine, Division of Cardiology, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA



Phone: (213)-977-4050

Fax: (213) 977-4107

Email: rkloner@goodsam.org

Univ.-Prof. Dr. med. Peter Hanrath, Director, Med. Klinik I, RWTH Universitaetsklinikum Aachen, Pauwelstrasse 30, 52074 Aachen, Germany



Phone: 0049-241-8089300

Fax: 0049-241-8082414

Email: med-klinik1@ukaachen.de

Prof. Dr. Dr. med. Wolfgang Schaper, Director, Max-Planck-Institut fuer experimentelle & physiolog. Forschung, W.-G. Kerckhoff Institut, Benekestrasse 2, Bad Nauheim, Germany



Phone: 0049-6032-705-402

Fax: 0049-6032-705419

Email: w.schaper@kerckhoff.mpg.de

Dr. Jose A. Loera, MD, Professor of Geriatrics, Texas A&M College ofMedicine, Chief, Section Geriatrics & Extended Care Central Texas Veterans Health Care System, Olin E Teague Veterans Medical Center, 1901 Veterans Memorial Drive, Geriatric Medicine Consultant,  Department of Internal Medicine Scott & White, Texas A&M Health Science Center-College of Medicine,  2401 South 31st Street,



Temple, Texas 76508, USA

Phone: (254) 742 4703

Email: jose.loera@va.gov and jloera@swmail.sw.org

Prof. Dr. Randall Urban, MD, Edward Randall & Edward Randall, Jr., Distinguished Chair in Internal Medicine, Professor and Chair, Department of Internal Medicine, Chairman of Medicine, The University of Texas Medical Branch, 301 University Blvd. John Sealy Annex,



Galveston,Texas 77555, USA , Email: rurban@utmb.edu

Phone: (409) 772 9891

http://intmed.utmb.edu/

Dr. Barry F. Uretsky, MD, Clinical Professor of Internal Medicine
Director of Interventional Cardiology Fellowship Program, UAMS
Director of Interventional Cardiology, CAVHS. University of Arkansas for Medical Sciences, Division of Cardiovascular Medicine



University of Arkansas for Medical Sciences
4301 W. Markham St., Little Rock, AR 72205

Email: BFUretsky@uams.edu

Dr. Parag Bharadwaj, MD, FAAHPM, Medical Director, Palliative Care Program, Cedars Sinai Medical Center, 870 Beverly Blvd., Ste. 2802, Los Angeles, CA 90048.


References

Dr. P.K. Shah, MD, Director, Division of Cardiology, Director, Oppenheimer Atheroscleroris Research Center, Professor of Medicine

, Cedars Sinai Medical Center & UCLA, , Shapell and Webb Family Chair in Clinical Cardiology, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd., Ste. 5531 , Los Angeles, CA 90048



Dr. Alfredo Trento, MD, Director of the Division of Cardiothoracic Surgery, Estelle, Abe and Marjorie Sanders Endowed Chair in Cardiac Surgery, Professor of Surgery at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Cedars Sinai Heart Institute, Cedars Sinai Medicla Center, 8700 Beverly Blvd., Ste. 2S03, Los Angeles, CA 90048.



Dr. Andrew Klein, MD, Director, Comprehensive Transplant Center, Professor of Surgery, Esther and Mark Schulman Chair in Surgery and Transplant Medicine, Cedars Sinai Medical Center, 8635 West 3rd St.
Suite 590W, Los Angeles, CA  90048



Dr. Bruce L. Gewertz, MD, Surgeon-in-Chief, H and S Nichols Endowed Chair in Surgery, Chairman, Department of Surgery, Vice-President for Interventional Services, Cedars-Sinai Medical Center, 8700 Beverly Blvd., 8215 NT Los Angeles, CA 90048



Prof. Dr. Robert A. Kloner, MD, PhD, Director, Heart Institute, Good Samaritan Hospital, Professor of Medicine, Division of Cardiology, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA



Univ.-Prof. Dr. med. Peter Hanrath, Director, Med. Klinik I, RWTH Universitaetsklinikum Aachen, Pauwelstrasse 30, 52074 Aachen, Germany



Prof. Dr. Dr. med. Wolfgang Schaper, Director, Max-Planck-Institut fuer experimentelle & physiolog. Forschung, W.-G. Kerckhoff Institut, Benekestrasse 2, Bad Nauheim, Germany



Dr. Jose A. Loera, MD, Professor of Geriatrics, Texas A&M College ofMedicine, Chief, Section Geriatrics & Extended Care Central Texas Veterans Health Care System, Olin E Teague Veterans Medical Center, 1901 Veterans Memorial Drive, Geriatric Medicine Consultant,  Department of Internal Medicine Scott & White, Texas A&M Health Science Center-College of Medicine,  2401 South 31st Street, Temple, Texas 76508, USA



Prof. Dr. Randall Urban, MD, Edward Randall & Edward Randall, Jr., Distinguished Chair in Internal Medicine, Professor and Chair, Department of Internal Medicine, Chairman of Medicine, The University of Texas Medical Branch, 301 University Blvd. John Sealy Annex, Galveston,Texas 77555, USA



Dr. Barry F. Uretsky, MD, Clinical Professor of Internal Medicine
Director of Interventional Cardiology Fellowship Program, UAMS
Director of Interventional Cardiology, CAVHS. University of Arkansas for Medical Sciences, Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences
4301 W. Markham St., Little Rock, AR 72205



Dr. Parag Bharadwaj, MD, FAAHPM, Medical Director, Palliative Care Program, Cedars Sinai Medical Center, 870 Beverly Blvd., Ste. 2802, Los Angeles, CA 90048